Title of article :
Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
Author/Authors :
Rajesh, V. Department of Pulmonary Medicine - Rajagiri Hospital, Chunangamvely, Aluva, Kochi, Kerala, India , Augustine, Jolsana Department of Pulmonary Medicine - Rajagiri Hospital, Chunangamvely, Aluva, Kochi, Kerala, India , Divya, R. Department of Pulmonary Medicine - Rajagiri Hospital, Chunangamvely, Aluva, Kochi, Kerala, India , Cleetus, Melcy Department of Pulmonary Medicine - Rajagiri Hospital, Chunangamvely, Aluva, Kochi, Kerala, India
Abstract :
Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled
corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been
shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of
administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one
among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the
combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the,
hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of
switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on
positioning it in real-world asthma management.